|
|
Article: Geron Restructuring Leaves Focus On Product Development.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Biotechnology is about cutting-edge research and it's about disease-fighting products. Those two go hand in hand, but when the markets tighten and fund raising becomes hard, developing products often takes the front seat.
That's the case at Menlo Park, Calif.-based Geron Corp., which said Monday it has restructured to focus on its most advanced product development programs, a move that was accompanied by a 30 percent cut in its work force, mostly research staff.
Clearly in focus now is the GRN163 cancer program that Geron hopes to kick into Phase I trials in 2003. The reduction of 33 research and 10 support staff positions - ...
Related newspaper, magazine, and journal articles:
|
|
Article: Geron Corporation and Genetic Therapy, Inc. Partner to ...
Business Wire;
January 7, 2002 ;
700+ words
... ... negative normal cells. Scientists at Geron have performed comprehensive tests ... replicated the results obtained by Geron. Taken together, these studies ... vector technology," said David L. Greenwood, Geron's chief financial officer and ...
|
|